Related Experiment Video

Updated: Jul 2, 2026

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Novel therapies in genitourinary cancer: an update

David Chu1, Shenhong Wu

  • 1Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USA. dchu@notes.cc.sunysb.edu

Journal of Hematology & Oncology
|August 13, 2008
PubMed

Insights

New targeted therapies offer improved survival and reduced toxicity for advanced renal cell carcinoma (RCC) and other genitourinary (GU) malignancies. This review highlights 2008 ASCO updates on these promising cancer treatments.

Area of Science:

  • Oncology
  • Urology
  • Cancer Therapeutics

Background:

  • Advanced renal cell carcinoma (RCC) and other genitourinary (GU) malignancies represent significant challenges in cancer care.
  • Traditional cytotoxic agents for these cancers often exhibit substantial toxicity.
  • The advent of targeted therapy has introduced novel treatment paradigms.

Purpose of the Study:

  • To review current and emerging treatment strategies for advanced RCC and other GU malignancies.
  • To provide updates from the 2008 ASCO annual meeting relevant to these cancers.
  • To discuss the potential benefits of new therapeutic agents, including improved survival and reduced toxicity.

Main Methods:

  • Literature review of recent advancements in cancer therapeutics.
  • Focus on targeted therapy agents for RCC and GU malignancies.
  • Inclusion of data and discussions from the 2008 ASCO annual meeting.

Main Results:

  • Emerging targeted therapy agents show promise for improved patient outcomes in advanced RCC and GU cancers.
  • These novel treatments may offer better survival rates compared to traditional chemotherapy.
  • Reduced toxicity profiles are anticipated with targeted therapy, enhancing patient quality of life.

Conclusions:

  • Targeted therapy represents a significant advancement in the treatment of advanced RCC and other GU malignancies.
  • Oncologists and urologists have increasing optimism regarding patient outcomes with these new agents.
  • Continued research and clinical updates, such as those from ASCO 2008, are crucial for optimizing treatment strategies.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...